aspc Search Results


aspc 1  (ATCC)
99
ATCC aspc 1
Aspc 1, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/aspc/AsPC-1/pm26830354-55-7-17
Average 99 stars, based on 1 article reviews
aspc 1 - by Bioz Stars, 2026-09
99/100 stars
  Buy from Supplier
aspc  (CLS Cell Lines Service GmbH)
94
CLS Cell Lines Service GmbH aspc
A) In vitro tumor spheroid (TS) assay to assess the treatment response to electroporation and CAR T-cell therapy. (1) TSs were formed within a low-adherent U-bottom 96-well, (2) then moved to a 4-well rectangular plate with low- conductivity buffer to (3) deliver electroporation via parallel plate electrodes. (4) The TSs were immediately moved back into the original U-bottom well, where (5) adjuvant CAR T-cells therapy or sham was delivered. B) Live (green) and dead (red) imaging <t>of</t> <t>AsPC-1</t> TSs at 3 hours and 72 hours after treatment for different electric field magnitudes; scale bar is 1 mm. Normalized absorbance for the XTT assay at C) 3 hours and D) 72 hours post-treatment at different electric fields; one-way ANOVA with Tukey’s post-test and correction; mean ± SD; n=3. E) Green fluorescent intensity of FLuc-eGFP + AsPC-1 TSs over time across different electric fields. F) Normalized GFP intensity and G) TS area over time; One-way ANOVAs with Tukey’s post hoc between groups on the last timepoints (*p < 0.05, *** p < 0.001, **** p<0.0001); Multiple One-Sample Wilcoxon signed-ranked tests between that timepoint and zero (# p < 0.05); n = 3.
Aspc, supplied by CLS Cell Lines Service GmbH, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/aspc/AsPC-1+Cells/bio_rxiv__2025__08__10__669537-182-7-5
Average 94 stars, based on 1 article reviews
aspc - by Bioz Stars, 2026-09
94/100 stars
  Buy from Supplier
human pancreatic adenocarcinoma cell line aspc  (ATCC)
96
ATCC human pancreatic adenocarcinoma cell line aspc
A) In vitro tumor spheroid (TS) assay to assess the treatment response to electroporation and CAR T-cell therapy. (1) TSs were formed within a low-adherent U-bottom 96-well, (2) then moved to a 4-well rectangular plate with low- conductivity buffer to (3) deliver electroporation via parallel plate electrodes. (4) The TSs were immediately moved back into the original U-bottom well, where (5) adjuvant CAR T-cells therapy or sham was delivered. B) Live (green) and dead (red) imaging <t>of</t> <t>AsPC-1</t> TSs at 3 hours and 72 hours after treatment for different electric field magnitudes; scale bar is 1 mm. Normalized absorbance for the XTT assay at C) 3 hours and D) 72 hours post-treatment at different electric fields; one-way ANOVA with Tukey’s post-test and correction; mean ± SD; n=3. E) Green fluorescent intensity of FLuc-eGFP + AsPC-1 TSs over time across different electric fields. F) Normalized GFP intensity and G) TS area over time; One-way ANOVAs with Tukey’s post hoc between groups on the last timepoints (*p < 0.05, *** p < 0.001, **** p<0.0001); Multiple One-Sample Wilcoxon signed-ranked tests between that timepoint and zero (# p < 0.05); n = 3.
Human Pancreatic Adenocarcinoma Cell Line Aspc, supplied by ATCC, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/aspc/AsPC-1%3B+Pancreatic+Cancer%3B+Human/pmc08144369-178-0-9
Average 96 stars, based on 1 article reviews
human pancreatic adenocarcinoma cell line aspc - by Bioz Stars, 2026-09
96/100 stars
  Buy from Supplier
pcmv ddk mouse aspscr1  (OriGene)
93
OriGene pcmv ddk mouse aspscr1
A) In vitro tumor spheroid (TS) assay to assess the treatment response to electroporation and CAR T-cell therapy. (1) TSs were formed within a low-adherent U-bottom 96-well, (2) then moved to a 4-well rectangular plate with low- conductivity buffer to (3) deliver electroporation via parallel plate electrodes. (4) The TSs were immediately moved back into the original U-bottom well, where (5) adjuvant CAR T-cells therapy or sham was delivered. B) Live (green) and dead (red) imaging <t>of</t> <t>AsPC-1</t> TSs at 3 hours and 72 hours after treatment for different electric field magnitudes; scale bar is 1 mm. Normalized absorbance for the XTT assay at C) 3 hours and D) 72 hours post-treatment at different electric fields; one-way ANOVA with Tukey’s post-test and correction; mean ± SD; n=3. E) Green fluorescent intensity of FLuc-eGFP + AsPC-1 TSs over time across different electric fields. F) Normalized GFP intensity and G) TS area over time; One-way ANOVAs with Tukey’s post hoc between groups on the last timepoints (*p < 0.05, *** p < 0.001, **** p<0.0001); Multiple One-Sample Wilcoxon signed-ranked tests between that timepoint and zero (# p < 0.05); n = 3.
Pcmv Ddk Mouse Aspscr1, supplied by OriGene, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/aspc/Aspscr1+(NM_001164224)+Mouse+Tagged+ORF+Clone/pmc12506973-308-11-16
Average 93 stars, based on 1 article reviews
pcmv ddk mouse aspscr1 - by Bioz Stars, 2026-09
93/100 stars
  Buy from Supplier
arylsulfatase aspctm  (Kura Biotech)
90
Kura Biotech arylsulfatase aspctm
A) In vitro tumor spheroid (TS) assay to assess the treatment response to electroporation and CAR T-cell therapy. (1) TSs were formed within a low-adherent U-bottom 96-well, (2) then moved to a 4-well rectangular plate with low- conductivity buffer to (3) deliver electroporation via parallel plate electrodes. (4) The TSs were immediately moved back into the original U-bottom well, where (5) adjuvant CAR T-cells therapy or sham was delivered. B) Live (green) and dead (red) imaging <t>of</t> <t>AsPC-1</t> TSs at 3 hours and 72 hours after treatment for different electric field magnitudes; scale bar is 1 mm. Normalized absorbance for the XTT assay at C) 3 hours and D) 72 hours post-treatment at different electric fields; one-way ANOVA with Tukey’s post-test and correction; mean ± SD; n=3. E) Green fluorescent intensity of FLuc-eGFP + AsPC-1 TSs over time across different electric fields. F) Normalized GFP intensity and G) TS area over time; One-way ANOVAs with Tukey’s post hoc between groups on the last timepoints (*p < 0.05, *** p < 0.001, **** p<0.0001); Multiple One-Sample Wilcoxon signed-ranked tests between that timepoint and zero (# p < 0.05); n = 3.
Arylsulfatase Aspctm, supplied by Kura Biotech, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/aspc/ASPC+recombinant+arylsulfatase++KuraBiotech++cat+no++ASPC+10+mL++lot+no++6604+1/pm33342568-69-1-6
Average 90 stars, based on 1 article reviews
arylsulfatase aspctm - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
26105 aspc cells/10 ul matrigel  (Becton Dickinson)
90
Becton Dickinson 26105 aspc cells/10 ul matrigel
A) In vitro tumor spheroid (TS) assay to assess the treatment response to electroporation and CAR T-cell therapy. (1) TSs were formed within a low-adherent U-bottom 96-well, (2) then moved to a 4-well rectangular plate with low- conductivity buffer to (3) deliver electroporation via parallel plate electrodes. (4) The TSs were immediately moved back into the original U-bottom well, where (5) adjuvant CAR T-cells therapy or sham was delivered. B) Live (green) and dead (red) imaging <t>of</t> <t>AsPC-1</t> TSs at 3 hours and 72 hours after treatment for different electric field magnitudes; scale bar is 1 mm. Normalized absorbance for the XTT assay at C) 3 hours and D) 72 hours post-treatment at different electric fields; one-way ANOVA with Tukey’s post-test and correction; mean ± SD; n=3. E) Green fluorescent intensity of FLuc-eGFP + AsPC-1 TSs over time across different electric fields. F) Normalized GFP intensity and G) TS area over time; One-way ANOVAs with Tukey’s post hoc between groups on the last timepoints (*p < 0.05, *** p < 0.001, **** p<0.0001); Multiple One-Sample Wilcoxon signed-ranked tests between that timepoint and zero (# p < 0.05); n = 3.
26105 Aspc Cells/10 Ul Matrigel, supplied by Becton Dickinson, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/aspc/26105+aspc+cells+10+ul+matrigel/pm22912777-236-5-6
Average 90 stars, based on 1 article reviews
26105 aspc cells/10 ul matrigel - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
aspc-1  (BioResource International Inc)
90
BioResource International Inc aspc-1
A) In vitro tumor spheroid (TS) assay to assess the treatment response to electroporation and CAR T-cell therapy. (1) TSs were formed within a low-adherent U-bottom 96-well, (2) then moved to a 4-well rectangular plate with low- conductivity buffer to (3) deliver electroporation via parallel plate electrodes. (4) The TSs were immediately moved back into the original U-bottom well, where (5) adjuvant CAR T-cells therapy or sham was delivered. B) Live (green) and dead (red) imaging <t>of</t> <t>AsPC-1</t> TSs at 3 hours and 72 hours after treatment for different electric field magnitudes; scale bar is 1 mm. Normalized absorbance for the XTT assay at C) 3 hours and D) 72 hours post-treatment at different electric fields; one-way ANOVA with Tukey’s post-test and correction; mean ± SD; n=3. E) Green fluorescent intensity of FLuc-eGFP + AsPC-1 TSs over time across different electric fields. F) Normalized GFP intensity and G) TS area over time; One-way ANOVAs with Tukey’s post hoc between groups on the last timepoints (*p < 0.05, *** p < 0.001, **** p<0.0001); Multiple One-Sample Wilcoxon signed-ranked tests between that timepoint and zero (# p < 0.05); n = 3.
Aspc 1, supplied by BioResource International Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/aspc/aspc+1/pm35364561-73-17-26
Average 90 stars, based on 1 article reviews
aspc-1 - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
human pancreatic cancer cell lines aspc-1  (DS Pharma Biomedical)
90
DS Pharma Biomedical human pancreatic cancer cell lines aspc-1
A) In vitro tumor spheroid (TS) assay to assess the treatment response to electroporation and CAR T-cell therapy. (1) TSs were formed within a low-adherent U-bottom 96-well, (2) then moved to a 4-well rectangular plate with low- conductivity buffer to (3) deliver electroporation via parallel plate electrodes. (4) The TSs were immediately moved back into the original U-bottom well, where (5) adjuvant CAR T-cells therapy or sham was delivered. B) Live (green) and dead (red) imaging <t>of</t> <t>AsPC-1</t> TSs at 3 hours and 72 hours after treatment for different electric field magnitudes; scale bar is 1 mm. Normalized absorbance for the XTT assay at C) 3 hours and D) 72 hours post-treatment at different electric fields; one-way ANOVA with Tukey’s post-test and correction; mean ± SD; n=3. E) Green fluorescent intensity of FLuc-eGFP + AsPC-1 TSs over time across different electric fields. F) Normalized GFP intensity and G) TS area over time; One-way ANOVAs with Tukey’s post hoc between groups on the last timepoints (*p < 0.05, *** p < 0.001, **** p<0.0001); Multiple One-Sample Wilcoxon signed-ranked tests between that timepoint and zero (# p < 0.05); n = 3.
Human Pancreatic Cancer Cell Lines Aspc 1, supplied by DS Pharma Biomedical, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/aspc/aspc+1/pm18037960-186-7-22
Average 90 stars, based on 1 article reviews
human pancreatic cancer cell lines aspc-1 - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
aspc-1 human pancreatic carcinoma cells  (European Collection of Authenticated Cell Cultures)
90
European Collection of Authenticated Cell Cultures aspc-1 human pancreatic carcinoma cells
A) In vitro tumor spheroid (TS) assay to assess the treatment response to electroporation and CAR T-cell therapy. (1) TSs were formed within a low-adherent U-bottom 96-well, (2) then moved to a 4-well rectangular plate with low- conductivity buffer to (3) deliver electroporation via parallel plate electrodes. (4) The TSs were immediately moved back into the original U-bottom well, where (5) adjuvant CAR T-cells therapy or sham was delivered. B) Live (green) and dead (red) imaging <t>of</t> <t>AsPC-1</t> TSs at 3 hours and 72 hours after treatment for different electric field magnitudes; scale bar is 1 mm. Normalized absorbance for the XTT assay at C) 3 hours and D) 72 hours post-treatment at different electric fields; one-way ANOVA with Tukey’s post-test and correction; mean ± SD; n=3. E) Green fluorescent intensity of FLuc-eGFP + AsPC-1 TSs over time across different electric fields. F) Normalized GFP intensity and G) TS area over time; One-way ANOVAs with Tukey’s post hoc between groups on the last timepoints (*p < 0.05, *** p < 0.001, **** p<0.0001); Multiple One-Sample Wilcoxon signed-ranked tests between that timepoint and zero (# p < 0.05); n = 3.
Aspc 1 Human Pancreatic Carcinoma Cells, supplied by European Collection of Authenticated Cell Cultures, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/aspc/aspc+1+human+pancreatic+carcinoma+cells/pm32514725-54-2-12
Average 90 stars, based on 1 article reviews
aspc-1 human pancreatic carcinoma cells - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
aspc‑1‑luc cells  (ProQinase GmbH)
90
ProQinase GmbH aspc‑1‑luc cells
A) In vitro tumor spheroid (TS) assay to assess the treatment response to electroporation and CAR T-cell therapy. (1) TSs were formed within a low-adherent U-bottom 96-well, (2) then moved to a 4-well rectangular plate with low- conductivity buffer to (3) deliver electroporation via parallel plate electrodes. (4) The TSs were immediately moved back into the original U-bottom well, where (5) adjuvant CAR T-cells therapy or sham was delivered. B) Live (green) and dead (red) imaging <t>of</t> <t>AsPC-1</t> TSs at 3 hours and 72 hours after treatment for different electric field magnitudes; scale bar is 1 mm. Normalized absorbance for the XTT assay at C) 3 hours and D) 72 hours post-treatment at different electric fields; one-way ANOVA with Tukey’s post-test and correction; mean ± SD; n=3. E) Green fluorescent intensity of FLuc-eGFP + AsPC-1 TSs over time across different electric fields. F) Normalized GFP intensity and G) TS area over time; One-way ANOVAs with Tukey’s post hoc between groups on the last timepoints (*p < 0.05, *** p < 0.001, **** p<0.0001); Multiple One-Sample Wilcoxon signed-ranked tests between that timepoint and zero (# p < 0.05); n = 3.
Aspc‑1‑Luc Cells, supplied by ProQinase GmbH, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/aspc/aspc+1+luc/pmc05423209-105-19-31
Average 90 stars, based on 1 article reviews
aspc‑1‑luc cells - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
aspc-1 cells stably transfected with a luciferase reporter construct  (JCRB Cell Bank)
90
JCRB Cell Bank aspc-1 cells stably transfected with a luciferase reporter construct
A) In vitro tumor spheroid (TS) assay to assess the treatment response to electroporation and CAR T-cell therapy. (1) TSs were formed within a low-adherent U-bottom 96-well, (2) then moved to a 4-well rectangular plate with low- conductivity buffer to (3) deliver electroporation via parallel plate electrodes. (4) The TSs were immediately moved back into the original U-bottom well, where (5) adjuvant CAR T-cells therapy or sham was delivered. B) Live (green) and dead (red) imaging <t>of</t> <t>AsPC-1</t> TSs at 3 hours and 72 hours after treatment for different electric field magnitudes; scale bar is 1 mm. Normalized absorbance for the XTT assay at C) 3 hours and D) 72 hours post-treatment at different electric fields; one-way ANOVA with Tukey’s post-test and correction; mean ± SD; n=3. E) Green fluorescent intensity of FLuc-eGFP + AsPC-1 TSs over time across different electric fields. F) Normalized GFP intensity and G) TS area over time; One-way ANOVAs with Tukey’s post hoc between groups on the last timepoints (*p < 0.05, *** p < 0.001, **** p<0.0001); Multiple One-Sample Wilcoxon signed-ranked tests between that timepoint and zero (# p < 0.05); n = 3.
Aspc 1 Cells Stably Transfected With A Luciferase Reporter Construct, supplied by JCRB Cell Bank, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/aspc/aspc+1+luc/pmc08881656-279-6-14
Average 90 stars, based on 1 article reviews
aspc-1 cells stably transfected with a luciferase reporter construct - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
aspc-1-gem  (Shanghai GenePharma)
90
Shanghai GenePharma aspc-1-gem
A) In vitro tumor spheroid (TS) assay to assess the treatment response to electroporation and CAR T-cell therapy. (1) TSs were formed within a low-adherent U-bottom 96-well, (2) then moved to a 4-well rectangular plate with low- conductivity buffer to (3) deliver electroporation via parallel plate electrodes. (4) The TSs were immediately moved back into the original U-bottom well, where (5) adjuvant CAR T-cells therapy or sham was delivered. B) Live (green) and dead (red) imaging <t>of</t> <t>AsPC-1</t> TSs at 3 hours and 72 hours after treatment for different electric field magnitudes; scale bar is 1 mm. Normalized absorbance for the XTT assay at C) 3 hours and D) 72 hours post-treatment at different electric fields; one-way ANOVA with Tukey’s post-test and correction; mean ± SD; n=3. E) Green fluorescent intensity of FLuc-eGFP + AsPC-1 TSs over time across different electric fields. F) Normalized GFP intensity and G) TS area over time; One-way ANOVAs with Tukey’s post hoc between groups on the last timepoints (*p < 0.05, *** p < 0.001, **** p<0.0001); Multiple One-Sample Wilcoxon signed-ranked tests between that timepoint and zero (# p < 0.05); n = 3.
Aspc 1 Gem, supplied by Shanghai GenePharma, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/aspc/aspc+1+gem/pmc06678460-40-26-30
Average 90 stars, based on 1 article reviews
aspc-1-gem - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier

Image Search Results


A) In vitro tumor spheroid (TS) assay to assess the treatment response to electroporation and CAR T-cell therapy. (1) TSs were formed within a low-adherent U-bottom 96-well, (2) then moved to a 4-well rectangular plate with low- conductivity buffer to (3) deliver electroporation via parallel plate electrodes. (4) The TSs were immediately moved back into the original U-bottom well, where (5) adjuvant CAR T-cells therapy or sham was delivered. B) Live (green) and dead (red) imaging of AsPC-1 TSs at 3 hours and 72 hours after treatment for different electric field magnitudes; scale bar is 1 mm. Normalized absorbance for the XTT assay at C) 3 hours and D) 72 hours post-treatment at different electric fields; one-way ANOVA with Tukey’s post-test and correction; mean ± SD; n=3. E) Green fluorescent intensity of FLuc-eGFP + AsPC-1 TSs over time across different electric fields. F) Normalized GFP intensity and G) TS area over time; One-way ANOVAs with Tukey’s post hoc between groups on the last timepoints (*p < 0.05, *** p < 0.001, **** p<0.0001); Multiple One-Sample Wilcoxon signed-ranked tests between that timepoint and zero (# p < 0.05); n = 3.

Journal: bioRxiv

Article Title: Novel combination of irreversible electroporation and allogenic chimeric antigen receptor (CAR) T-cell therapy synergizes therapeutic outcomes in a preclinical human pancreatic cancer mouse model

doi: 10.1101/2025.08.10.669537

Figure Lengend Snippet: A) In vitro tumor spheroid (TS) assay to assess the treatment response to electroporation and CAR T-cell therapy. (1) TSs were formed within a low-adherent U-bottom 96-well, (2) then moved to a 4-well rectangular plate with low- conductivity buffer to (3) deliver electroporation via parallel plate electrodes. (4) The TSs were immediately moved back into the original U-bottom well, where (5) adjuvant CAR T-cells therapy or sham was delivered. B) Live (green) and dead (red) imaging of AsPC-1 TSs at 3 hours and 72 hours after treatment for different electric field magnitudes; scale bar is 1 mm. Normalized absorbance for the XTT assay at C) 3 hours and D) 72 hours post-treatment at different electric fields; one-way ANOVA with Tukey’s post-test and correction; mean ± SD; n=3. E) Green fluorescent intensity of FLuc-eGFP + AsPC-1 TSs over time across different electric fields. F) Normalized GFP intensity and G) TS area over time; One-way ANOVAs with Tukey’s post hoc between groups on the last timepoints (*p < 0.05, *** p < 0.001, **** p<0.0001); Multiple One-Sample Wilcoxon signed-ranked tests between that timepoint and zero (# p < 0.05); n = 3.

Article Snippet: Pan02 mouse pancreatic cancer cells (Cytion, 300501), AsPC-1 human pancreatic cancer (CRL-1682), and Jurkat immortalized human T-lymphocytes (ATCC, TIB-152) were cultured in RPMI-1640 medium (ThermoFisher, 11875093) supplemented with 10% (v/v) fetal bovine serum (Fisher Scientific, FB12999102) and 1% (v/v) 10,000 U/ml penicillin-streptomycin (Gibco, 16140122).

Techniques: In Vitro, Electroporation, Adjuvant, Imaging, XTT Assay

A) Green fluorescent intensity of FLuc-eGFP + AsPC-1 TS, B) deep-red intensity of cell tracker- stained CAR T-cells, and C) merged image over time for the CAR T-cell only and combinatorial treatment (both). D) Measured TS area and E) normalized eGFP intensity over time; One-way ANOVAs with Tukey’s post hoc between groups on the last time points (*p < 0.05, ** p< 0.01, *** p < 0.001, **** p<0.0001); n ≥ 3. F) Comparison of deep-red intensity within the tumor spheroid over time; Two-tailed T-tests between groups at each timepoint (# p < 0.05, ## p < 0.01), n ≥ 3.

Journal: bioRxiv

Article Title: Novel combination of irreversible electroporation and allogenic chimeric antigen receptor (CAR) T-cell therapy synergizes therapeutic outcomes in a preclinical human pancreatic cancer mouse model

doi: 10.1101/2025.08.10.669537

Figure Lengend Snippet: A) Green fluorescent intensity of FLuc-eGFP + AsPC-1 TS, B) deep-red intensity of cell tracker- stained CAR T-cells, and C) merged image over time for the CAR T-cell only and combinatorial treatment (both). D) Measured TS area and E) normalized eGFP intensity over time; One-way ANOVAs with Tukey’s post hoc between groups on the last time points (*p < 0.05, ** p< 0.01, *** p < 0.001, **** p<0.0001); n ≥ 3. F) Comparison of deep-red intensity within the tumor spheroid over time; Two-tailed T-tests between groups at each timepoint (# p < 0.05, ## p < 0.01), n ≥ 3.

Article Snippet: Pan02 mouse pancreatic cancer cells (Cytion, 300501), AsPC-1 human pancreatic cancer (CRL-1682), and Jurkat immortalized human T-lymphocytes (ATCC, TIB-152) were cultured in RPMI-1640 medium (ThermoFisher, 11875093) supplemented with 10% (v/v) fetal bovine serum (Fisher Scientific, FB12999102) and 1% (v/v) 10,000 U/ml penicillin-streptomycin (Gibco, 16140122).

Techniques: Staining, Comparison, Two Tailed Test